Latest Articles

Publication Date
All News Scientific
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - The AI Journal

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer The AI Journal

Published: Oct. 18, 2025, 10:20 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational - GlobeNewswire

Genmab Announces New Data Demonstrating Investigational GlobeNewswire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - GlobeNewswire

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer GlobeNewswire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Yahoo Finance

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Yahoo Finance

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
The best October Prime Day 2025 Satisfyer deals - Mashable

The best October Prime Day 2025 Satisfyer deals Mashable

Published: Oct. 18, 2025, 8:13 a.m.
Read Full Article
The female scientists who finally found an answer to endometriosis wait times - The i Paper

The female scientists who finally found an answer to endometriosis wait times The i Paper

Published: Oct. 18, 2025, 5 a.m.
Read Full Article
Is AFBI stock a contrarian buy - Portfolio Risk Report & Weekly Return Optimization Plans - Trung tâm Dự báo KTTV quốc gia

Is AFBI stock a contrarian buy - Portfolio Risk Report & Weekly Return Optimization Plans Trung tâm Dự báo KTTV quốc gia

Published: Oct. 18, 2025, 2:22 a.m.
Read Full Article
Endometriosis diagnosis wait cut from years to just weeks in major breakthrough - MSN

Endometriosis diagnosis wait cut from years to just weeks in major breakthrough MSN

Published: Oct. 17, 2025, 10:05 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!